PUMA BIOTECHNOLOGY INC (PBYI)

Price$7.03

Value ScoreB

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)31.28%

Price vs S&P 500 (4W)-6.13%

VGM Score62.24

Market Capitalization$357.31M

P/E Ratio (Annual)11.49x

All Metrics

P/CF (Annual)8.55x

Book Value / Share (Quarterly)$2.52

P/TBV (Annual)3.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)0.05%

Cash Flow / Share (Quarterly)$1.05

Price vs S&P 500 (YTD)9.99%

Gross Margin (TTM)74.46%

Net Profit Margin (TTM)10.73%

EPS (TTM)$0.48

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$0.48

Revenue Growth (5Y)0.29%

EPS (Annual)$0.61

ROI (Annual)20.35%

Gross Margin (Annual)74.53%

Net Profit Margin (5Y Avg)4.89%

Cash / Share (Quarterly)$2.00

P/E Basic Excl Extra (TTM)14.65x

Revenue Growth QoQ (YoY)-2.59%

P/E Normalized (Annual)11.49x

ROA (Last FY)14.38%

Revenue Growth TTM (YoY)-2.38%

EBITD / Share (TTM)$0.79

ROE (5Y Avg)-66.97%

Operating Margin (TTM)12.98%

Cash Flow / Share (Annual)$0.83

P/B Ratio2.78x

P/B Ratio (Quarterly)2.53x

Net Income / Employee (Annual)$173,800

EV / Revenue (TTM)1.46x

Net Interest Coverage (TTM)15.07x

ROA (TTM)12.09%

EPS Growth QoQ (YoY)-33.47%

EV / EBITDA (TTM)8.27x

EPS Incl Extra (Annual)$0.61

Current Ratio (Annual)2.00x

Quick Ratio (Quarterly)2.18x

3-Month Avg Trading Volume0.34M

52-Week Price Return92.60%

EV / Free Cash Flow (Annual)7.97x

P/E Incl Extra (TTM)14.65x

Revenue / Employee (TTM)$1,269,200

Tangible BV / Share (Quarterly)$1.76

P/S Ratio (Annual)1.56x

Asset Turnover (Annual)1.06x

52-Week High$7.90

Operating Margin (5Y Avg)8.42%

EPS Excl Extra (Annual)$0.61

CapEx CAGR (5Y)-67.65%

26-Week Price Return39.21%

Quick Ratio (Annual)1.89x

13-Week Price Return12.84%

Total Debt / Equity (Annual)0.17x

Current Ratio (Quarterly)2.38x

Enterprise Value$332.40M

Revenue / Share Growth (5Y)-4.53%

Asset Turnover (TTM)1.13x

Book Value / Share Growth (5Y)23.62%

Revenue / Employee (Annual)$1,275,800

Inventory Turnover (Annual)8.17x

Pretax Margin (Annual)15.67%

Cash / Share (Annual)$1.93

3-Month Return Std Dev37.03%

Gross Margin (5Y Avg)74.13%

Net Income / Employee (TTM)$136,200

ROE (Last FY)23.87%

Net Interest Coverage (Annual)15.07x

EPS Basic Excl Extra (Annual)$0.61

P/FCF (TTM)6.67x

Receivables Turnover (TTM)8.82x

EV / Free Cash Flow (TTM)6.20x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$0.48

Receivables Turnover (Annual)5.33x

ROI (TTM)16.50%

P/S Ratio (TTM)1.57x

Pretax Margin (5Y Avg)4.92%

Revenue / Share (Annual)$4.51

Tangible BV / Share (Annual)$1.76

Forward P/E27.74x

Free OCF CAGR (5Y)11.98%

Price vs S&P 500 (52W)68.24%

P/E Ratio (TTM)14.65x

EPS Growth TTM (YoY)-38.07%

Year-to-Date Return18.15%

5-Day Price Return-1.26%

EPS Normalized (Annual)$0.61

ROA (5Y Avg)5.02%

Net Profit Margin (Annual)13.62%

Month-to-Date Return-1.95%

Cash Flow / Share (TTM)$0.31

EBITD / Share (Annual)$0.95

Operating Margin (Annual)16.33%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)6.67x

ROI (5Y Avg)-2.75%

P/E Excl Extra (TTM)14.65x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.48

P/TBV (Quarterly)3.63x

P/B Ratio (Annual)2.30x

Inventory Turnover (TTM)6.65x

Pretax Margin (TTM)12.80%

Book Value / Share (Annual)$2.59

Price vs S&P 500 (13W)4.59%

Beta1.26x

P/FCF (Annual)8.56x

Revenue / Share (TTM)$4.47

ROE (TTM)20.37%

52-Week Low$3.03

vGradeB

gGradeD

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.07est. -0.13

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

2.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PBYIPUMA BIOTECHNOLOGY INC	B	D	B	$7.03
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Puma Biotechnology is an oncology-focused biopharmaceutical company that commercializes NERLYNX, an oral medication for HER2-positive breast cancer, and is developing alisertib, an aurora kinase A inhibitor. The company targets improvements in cancer treatment outcomes through its portfolio of targeted therapies.